Hip Osteoarthritis Pain Drug Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)

Hip Osteoarthritis Pain Drug Market is anticipated to grow at a significant CAGR during the forecast period. The common symptoms of hip osteoarthritis include pain around groin area of the hip (area between the upper thigh and lower abdomen). Generally, this pain starts gradually and gets worsen over time if not treated on time. The major factors attributable to the growth of the hip osteoarthritis pain drug market include the rising prevalence of hip osteoarthritis due to aging, excess weight gain, and in some cases, due to genetic causes. It majorly affects the articular cartilage which results in changes to synovium, ligaments, capsules, and subchondral bone. According to the World Health Organization (WHO), hip osteoarthritis stands in top 15 contributors of global disability. Additionally, it is mainly diagnosed in people of age above 65, where 50% of the cases are symptomatic. In addition, as per the survey conducted by the Centers for Disease Control and Prevention (CDC), lifetime risk has been associated with hip osteoarthritis which is 18.5% for men, and 28.6% for women.

Some key players operating in the market include Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Bayer AG, among others. These market players are continuously focusing on introducing new drug drugs catering to cure the pain of hip or knee joints. For instance, in May 2020, Novartis introduced a new drug named as interleukin-1 inhibitor canakinumab, which will relatively reduce the overall of the cost associated with hip or knee replacement and will also decrease osteoarthritis symptoms. The drug has been published by Annals of Internal Medicine later in November 2020 stating the advantages of the drugs.

To Request a Sample of our Report on Hip Osteoarthritis Pain Drug Market: https://www.omrglobal.com/request-sample/hip-osteoarthritis-pain-drug-market

Market Coverage

· The market number available for - 2023-2030

· Base year- 2023

· Forecast period- 2024-2030

Segment Covered-

· By Type

· By Distribution Channel

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Bayer AG, among others.

A full Report of Hip Osteoarthritis Pain Drug Market is Available @ https://www.omrglobal.com/industry-reports/hip-osteoarthritis-pain-drug-market

Hip Osteoarthritis Pain Drug Market Report by Segment

By Type

· Oral

· Injection

· Others

By Distribution Channel

· Online

· Offline

Global Hip Osteoarthritis Pain Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.